A combination vaccine is a mixture of two or more than two vaccines
that could be administered separately, which is put into a single shot.
The combination vaccine offers the same protection to children as the
two vaccines administered separately, but with a few number of shots.
Disease prevention and eradication of preventable diseases are eventual
and instant goals of immunization and the method to achieve these goals
is maintaining vaccine coverage. Vaccine coverage can be maintained by
using combination vaccines, as they simplify the schedule of vaccination
and reduce the number of injections required.
The development of combination vaccines for protection against
multiple diseases was initiated by combining separate vaccines against
tetanus, diphtheria, and pertussis into a single product. This
combination of diphtheria, pertussis, and tetanus vaccines into a single
product has been crucial for protection of children. Similarly, the
combination of inactivated polio, hepatitis B, and Haemophilus
influenzae vaccines has enabled the inclusion of these vaccines into
recommended immunization schedules, by reducing the number of injections
required. This has also increased the immunization compliance. However,
numerous challenges are faced while developing these combinations
including the abridged response to the Haemophilus influenzae
vaccine when administered in combination. There is immediate need to
expand the safety profile of the tetanus, diphtheria, and pertussis
combination vaccine.
An important development in the field of combination vaccines was replacement of whole-cell pertussis antigens with less reactogenic acellular antigens. This paved the way for combining of tetanus, diphtheria, and acellular pertussis antigens with other routinely used vaccines such as inactivated Haemophilus influenzae vaccine, polio vaccine, and hepatitis B vaccine. Another significant combination vaccine that gives protection against more than one disease is the mumps, measles, and rubella (MMR) vaccine. A few examples of commonly used combination vaccines in children are: ProQuad, which combines MMR and varicella; Pediarix, which combines Hep B, DTaP, and IPV; Pentacel, which combines DTaP, IPV, and Hib; and Kinrix, which combines IPV and DTaP.
The global combination vaccines market is driven by increase in the
prevalence of infectious diseases. Infectious diseases is one of the
most leading causes of illnesses and deaths worldwide. In developing
countries with weak health care infrastructure, influence of infectious
diseases is even devastating, leading to reduced survival rates,
particularly in children and hampering the economy. The increase in
pediatric population is one of the primary drivers for the global
combination vaccines market. With the increase in pediatric population,
the demand for combination vaccines for immunization has increased, as
infants are more susceptible to various infectious diseases due to their
weak immune systems. Occurrence of viral infections and diseases such
as polio, tetanus, diphtheria, smallpox, chickenpox, and measles has
been observed to be high among children in developing countries. This is
anticipated to drive the demand for combination vaccines during the
forecast period. As scientists are developing and testing new vaccines
to protect children from more diseases, more combination vaccines may
become available in the near future. This would allow children to get
additional protection with a fewer number of shots.
The global combination vaccines market can be segmented into five
major regions: North America, Europe, Asia Pacific, Latin America, and
Middle East & Africa. Asia Pacific is projected to register a high
CAGR during the forecast period, due to rising pediatric population and
increasing awareness about vaccination in the region. Continuous efforts
by market players and national organizations to promote the use of
combination vaccines would drive the market in developed countries in
the near future.
Key players operating in the global combination vaccines market include GlaxoSmithKline, Merck & Co., Inc., Sanofi Aventis, Pfizer, Inc., Novartis AG, and Takeda Pharmaceutical Company Limited.
An important development in the field of combination vaccines was replacement of whole-cell pertussis antigens with less reactogenic acellular antigens. This paved the way for combining of tetanus, diphtheria, and acellular pertussis antigens with other routinely used vaccines such as inactivated Haemophilus influenzae vaccine, polio vaccine, and hepatitis B vaccine. Another significant combination vaccine that gives protection against more than one disease is the mumps, measles, and rubella (MMR) vaccine. A few examples of commonly used combination vaccines in children are: ProQuad, which combines MMR and varicella; Pediarix, which combines Hep B, DTaP, and IPV; Pentacel, which combines DTaP, IPV, and Hib; and Kinrix, which combines IPV and DTaP.
Key players operating in the global combination vaccines market include GlaxoSmithKline, Merck & Co., Inc., Sanofi Aventis, Pfizer, Inc., Novartis AG, and Takeda Pharmaceutical Company Limited.
No comments:
Post a Comment